NASDAQ:INMB INmune Bio Q3 2026 Earnings Report $1.95 -0.01 (-0.51%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$2.01 +0.06 (+3.28%) As of 09/30/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast INmune Bio EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/AINmune Bio Revenue ResultsActual RevenueN/AExpected Revenue$1.88 millionBeat/MissN/AYoY Revenue GrowthN/AINmune Bio Announcement DetailsQuarterQ3 2026Date10/29/2026TimeAfter Market ClosesConference Call DateThursday, October 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile INmune Bio Earnings HeadlinesINmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To BoardSeptember 15, 2026 | rttnews.comINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to BoardSeptember 14, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)INmune Bio to Present at the H.C. Wainwright Global Investment ConferenceSeptember 9, 2026 | globenewswire.comINmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory AlignmentAugust 28, 2026 | seekingalpha.comINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory FilingsAugust 26, 2026 | globenewswire.comSee More INmune Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like INmune Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INmune Bio and other key companies, straight to your email. Email Address About INmune BioINmune Bio (NASDAQ:INMB) is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions. Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer’s disease and treatment-resistant depression. The company’s second platform, INKmune, is designed to activate a patient’s natural killer cells and is being developed as an oncology immunotherapy. INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. Its clinical development activities have included studies in the United States and other regions. The company is led by Chief Executive Officer and co-founder R. J. Tesi, M.D., who has a background in medicine, oncology and biotechnology.View INmune Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
